Drugs / MVA.HIVA
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00982579 | Nov 2009 → Jun 2011 | HIV infectious disease | Medical Research Council | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00981695 | Nov 2009 → Jul 2011 | HIV infectious disease, HIV-associated cancer | Medical Research Council | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01371175 | Apr 2003 → May 2005 | HIV infectious disease | International AIDS Vaccine Initiative | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MVA.HIVA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00982579 ↗ |
| Modality | Vaccine | “This trial tested for the first time an MVA-vectored candidate HIV-1 vaccine in HIV-1-exposed infants in Africa” PMID 25173484 ↗ Aug 2014 |
| Route | Intramuscular | “a single, low dose of MVA.HIVA vaccine delivered intramuscularly to healthy 20-week-old infants born to HIV-1-positive mothers in Nairobi, Kenya” PMID 25173484 ↗ Aug 2014 |